Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids Market, 2030 - Current Market Landscape and the Likely Future Adoption of Such Technologies

News provided by

Apr 01, 2019, 10:15 ET

DUBLIN, April 1, 2019 /PRNewswire/ -- The "Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Novel Technologies for Delivery of Proteins, Antibodies, and Nucleic Acids, 2019-2030 report features an extensive study of the current market landscape and the likely future adoption of such technologies, over the next twelve years.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the administration of proteins, antibodies, and nucleic acids. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2018-2030.

The report features likely distribution of the current and forecasted opportunity across the [A] type of therapeutic area (oncology and non-oncology), [B] route of administration (parenteral and non-parenteral), [C] key contributing technologies and [D] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The study features in-depth analysis, highlighting:

A detailed assessment of the current market landscape of companies offering technologies for delivery of biotherapeutics, including information on their geographical location, types of biologics delivered (proteins, peptides, antibodies and nucleic acids), routes of administration used (parenteral, oral, transdermal / topical, inhalation and others) and impact on drug properties / patient compliance.
A comprehensive competitiveness analysis of the drug delivery technologies captured in our report database, taking into consideration the supplier power (based on year of establishment) and key technology-related specifications, such as the type(s) of biologics delivered, the extent of the impact on drug properties, patient compliance and the route of administration.
Elaborate profiles of prominent technology developers engaged in this domain, featuring a brief overview of the company, its financial performance (if available), information on its product portfolio, recent developments and a comprehensive future outlook. Additionally, the report includes profiles of certain technologies that emerged as relatively superior in our proprietary competitiveness analysis.
An in-depth analysis of the various patents that have been filed and granted related to novel drug delivery technologies, till November 2018. It includes information on key parameters, such as patent type, publication year, issuing authority, CPC classification, emerging focus areas and leading industry / academic players (in terms of the size of the intellectual property portfolio).
A detailed analysis of the partnerships and collaborations focused on technologies for the delivery of biotherapeutics, featuring a comprehensive set of analyses based on various parameters, such as the year of establishment, type of partnership, type of therapeutic areas, most active players and geographical location.
A discussion on the upcoming opportunities in the field of biotherapeutic drug delivery that are likely to impact the evolution of this market in the coming years.

Key Topics Covered:

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. An Overview of Biopharmaceuticals
3.2. Demand for Biopharmaceuticals
3.3. Types of Biopharmaceuticals
3.3.1. Proteins and Peptides
3.3.2. Antibodies
3.3.3. Nucleic Acids
3.4. Common Routes of Administration for Biopharmaceuticals
3.4.1. Parenteral Delivery
3.4.1.1. Intravenous Route
3.4.1.2. Intramuscular Route
3.4.1.3. Subcutaneous Route
3.4.2. Non-Parenteral Delivery
3.4.2.1. Buccal / Sublingual Route
3.4.2.2. Intranasal Route
3.4.2.3. Inhalation / Pulmonary Route
3.4.2.4. Ocular Route
3.4.2.5. Oral Route
3.4.2.6. Rectal Route
3.4.2.7. Transdermal Route
3.5. Key Challenges Associated with Drug Delivery
3.6. Advanced Approaches for Delivery of Biotherapeutics
3.6.1. Muco-Adhesive Polymeric Systems
3.6.2. Nanoparticle-based Delivery Systems
3.6.3. Other Drug Delivery Technologies
3.7. Demand for Novel Drug Delivery Technologies
3.8. Concluding Remarks

4. Market Landscape
4.1. Chapter Overview
4.2. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Overall Market Landscape
4.2.1. Analysis by Size of Developer Company
4.2.2. Analysis by Year of Establishment
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Biologics Delivered
4.2.5. Analysis by Impact of Technology on Drug Properties / Patient Compliance
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Geographical Location of Developer Company
4.3. Grid Analysis: Distribution by Type of Biologics, Route of Administration and Drug Delivery Parameters
4.4. List of Drug Formulation Technologies

5. Product Competitiveness Analysis
5.1. Chapter Overview
5.2. Product Competitiveness Analysis: Key Assumptions and Methodology
5.2.1. Technologies of Companies Based in North America
5.2.2. Technologies of Companies Based in Europe
5.2.3. Technologies of Companies Based in Asia-Pacific

6. Technology Profiles
6.1. Chapter Overview
6.2. Intravail Technology
6.3. RapidMist
6.4. TheraKine Technology
6.5. Arestat Technology
6.6. DelSiTech Silica Matrix
6.7. ImSus Technology
6.8. PLEX Technology
6.9. ENHANZE Technology

7. Company Profiles: Drug Delivery Platform Providers
7.1. Chapter Overview
7.2. Aphios
7.3. Arbutus Biopharma
7.4. Camurus
7.5. ConjuChem
7.6. InnoCore Pharmaceuticals
7.7. LATITUDE Pharmaceuticals

8. Patent Analysis
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Issuing Authority / Patent Offices Involved
8.3.3. Analysis by CPC Classification
8.3.4. Emerging Focus Areas
8.3.5. Leading Players Based on Number of Patents
8.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.4.2. Analysis by Geography
8.5. Novel Technologies for Proteins, Antibodies and Nucleic Acids: Patent Valuation Analysis

9. Recent Partnerships
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Technologies for Proteins, Antibodies and Nucleic Acids: List of Partnerships and Collaborations

10. Market Sizing And Opportunity Analysis
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Information on Licensing Deals
10.4. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Overall Market, 2019-2030
10.5. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Region, 2019 and 2030
10.6. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Therapeutic Area, 2019 and 2030
10.7. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market Attractiveness Analysis by Therapeutic Areas
10.8. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Distribution by Route of Delivery, 2019 and 2030
10.9. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids: Market for Key Contributing Technologies, 2019 and 2030

11. Future Growth Opportunities
11.1. Chapter Overview
11.2. The Industry Has Recently Witnessed A Shift from Conventional Nanoparticle-Based Technologies to DNA-Based Solutions
11.3. Despite Extensive Research Efforts in this Domain, There is Still A Substantial Unmet Need Related To Drug Delivery Technologies For Neurodegenerative Disorders
11.4. The Oral Route of Delivery, Owing to its Capability to Ensure Therapy Adherence, Has Garnered Significant Attention in this Market
11.5. Impending Patent Expirations Have Prompted Many Players to Adopt Various Life Cycle Management Strategies to Sustain Revenue Generation Potential
11.6. The Larger Market Share is Currently with the Developed Regions, while Contributions from Technology Providers in the Asia Pacific are Expected to Increase in the Foreseen Future

12. Executive Insights
12.1. Chapter Overview
12.2. ArmaGen
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Mathias Schmidt, Chief Executive Officer
12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder
12.4. KAER Biotherapeutics
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Donovan Yeates, Chief Executive Officer and Chief Scientific Officer, Chairman and Founder

13. Appendix 1: Tabulated Data

14. Appendix 2: List Of Companies And Organizations

4P Therapeutics
Abbott Laboratories
AbbVie
Acuitas Therapeutics
ADAMA
Adhera Therapeutics
Adimab
ADOCIA
Aegis Therapeutics
Aerogen
AIMM Therapeutics
Ajinomoto Bio-Pharma Services
Albireo Pharma
Alchemia
Alexion Pharmaceuticals
Allergan
ALRISE Biosystems
Alteogen
AMAG Pharmaceuticals
Amarantus BioScience Holdings
Amgen
Antares Pharma
Antibody Solutions
Aphios
Applied Molecular Transport
Apricus Biosciences
Aquarius Biotechnologies
Aquestive Therapeutics
Aradigm
Arbutus Biopharma
Arecor
ArmaGen
Ascendis Pharma
Astellas Research Institute of America
AstraZeneca
Avadel Pharmaceuticals
Bausch Health Companies
Baxter International
Bayer
BBI Solutions
BGN Technologies
Bio-Path Holdings
Bioasis Technologies
BioCardia
BioCorRx
Biogen
BiondVax Pharmaceuticals
Biovail Laboratories
Boehringer Ingelheim
Brigham and Women's Hospital
Bristol-Myers Squibb
C-TRI
Caisson Biotech
Camurus
CannScience Innovations
Capsugel
Catalent Pharma Solutions
Cell Care Therapeutics
Centre for Process Innovation
Cerenis Therapeutics
Chembio Diagnostics
Chugai Pharmaceutical
ConjuChem Biotechnologies
CordenPharma
Corium International
CSL Behring
Cureport
Dauntless Pharmaceuticals
Delpor
DelSiTech
Dendreon
Diabetology
Dicerna Pharmaceuticals
Dr Reddy's Laboratories
Eisai
Elasmogen
Eli Lilly and Company
Elusys Therapeutics
Emergent BioSolutions
Emergent Technology
Emisphere Technologies
enGene
Engineered BioPharmaceuticals
Epeius Biotechnologies
EuMederis Pharmaceuticals
Evonik
Excelse Bio
Exicure
Feldan Therapeutics
Ferring Pharmaceuticals
Flex
Foresee Pharmaceuticals
FUJIFILM Diosynth Biotechnologies
Genentech
Generex Biotechnology
Genexine
Genisphere
Genmab
GlaxoSmithKline
Graybug Vision
Green Cross Labcell
Gritstone Oncology
Halozyme Therapeutics
Heron Therapeutics
Hovione
Human Stem Cells Institute
ICB International
Ichor Medical Systems
ImClone Systems
Indivior UK
InnoCore Pharmaceuticals
Inovio Pharmaceuticals
Inserm
InteRNA Technologies
Invenra
Ionis Pharmaceuticals
Janssen Pharmaceuticals
Jerini
Johnson & Johnson
KAER Biotherapeutics
Kolon Life Science
Kolon TissueGene
Kurve Technology
Kyowa Hakko Kirin
Lankenau Institute for Medical Research (LIMR)
LATITUDE Pharmaceuticals
Lauren Sciences
Longevity Biotech
Lupin Pharmaceuticals
Lyndra Therapeutics
MannKind
Matinas BioPharma
Medesis Pharma
MedImmune
Merck
Merrion Pharmaceuticals
Merz Pharma
MiNA Therapeutics
Mitsubishi Tanabe Pharma
MonoSol
Monsanto
Mountain View Pharmaceuticals
MultiCell Technologies
Mylan
Nanexa
NanoCarrier
Nanomi
National Institute of Neurological Disorders and Stroke
NBE-Therapeutics
Neurelis
NHTherapeutics
NOD Pharmaceuticals
Novartis
Novo Nordisk
Novosom
Nutriband
Oakwood Labs
Octapharma
Ocular Therapeutix
Oncotelic
Opiant Pharmaceuticals
OPKO Biologics
Oramed Pharmaceuticals
Orbis Biosciences
Pacira Pharmaceuticals
Peptineo
Peptron
PepVax
Pfizer
PharmaIN
PhaseBio Pharmaceuticals
Phylogica
Pickwick Capital Partners
PolyPid
Precision NanoSystems
Profectus BioSciences
Prometheon Pharma
Prometheus Laboratories
Prothena
Proxima Concepts
Pulmatrix
Purdue Pharma
Rani Therapeutics
Receptor Life Sciences
Regeneron Pharmaceuticals
Rett Syndrome Research Trust
rEVO Biologics
Rhythm Pharmaceuticals
Roche
Roivant Sciences
RoverMed BioSciences
San Diego Hospice and The Institute for Palliative Medicine
Sanofi
Savient Pharmaceuticals
ScinoPharm
Scripps Research
Serina Therapeutics
Seton Healthcare Family
Shanghai Sunway Biotech
Sibiono GeneTech
Sierra Oncology
SmooFi
Solani Therapeutics
Spark Therapeutics
Strides Pharma Science
SUDA Pharmaceuticals
Swedish Orphan Biovitrum
Synthelis
Takeda Oncology
Takeda Pharmaceutical
Tamarisk Technologies Group
Tarix Pharmaceuticals
Teva Pharmaceutical Industries
Teva Respiratory
The Jordanian Pharmaceutical Manufacturing
Theraclone Sciences
TheraKine
Thomas Jefferson University
Transdermal
UCB
University of Maryland
University of North Texas Health Science Center
University of Pennsylvania
Valerion Therapeutics
Velocity Pharmaceutical Development
Vical
ViroPharma
ViroVet
Xenetic Biosciences
XL-protein

For more information about this report visit https://www.researchandmarkets.com/r/m6753f

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets